Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in Laguna Hills, California and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
